Glycogen storage disease prevent low blood sugar, while other treatments may include allopurinol and human granulocyte colony stimulating factor. Overall, according to a study in British Columbia, approximately 2.3 children per 100,000 births (1 in 43,000) have some form of glycogen storage disease. In the United States, they are estimated to occur in 1 per 20,000–25,000 births. Dutch incidence rate is estimated to be 1 per 40,000 births. Glycogen storage disease A glycogen storage disease (GSD, also glycogenosis and dextrinosis) is a metabolic disorder caused by enzyme deficiencies affecting either glycogen synthesis, glycogen breakdown or glycolysis (glucose breakdown), typically within muscles and/or liver
(glycogen-synthase-D) phosphatase 2_degree_C. (glycogen-synthase-D) phosphatase In enzymology, a [glycogen-synthase-D] phosphatase () is an enzyme that catalyzes the chemical reaction Thus, the two substrates of this enzyme are glycogen-synthase D and HO, whereas its two products are glycogen-synthase I and phosphate. This enzyme belongs to the family of hydrolases, specifically those acting on phosphoric monoester bonds. The systematic name of this enzyme class is [UDP-glucose:glycogen 4-alpha-D-glucosyltransferase-D] phosphohydrolase. Other names in common use include uridine diphosphoglucose-glycogen glucosyltransferase phosphatase, UDP-glycogen glucosyltransferase phosphatase, UDPglucose-glycogen glucosyltransferase phosphatase, glycogen glucosyltransferase phosphatase, glycogen synthetase phosphatase, glycogen synthase phosphatase, glycogen synthase D phosphatase, Mg dependent glycogen synthase phosphatase, and phosphatase